Cancer News

Breast cancer is the most common cancer specific to women. An eight-page a oeSpecial Reporta on breast cancer in the June issue of Mayo Clinic Health Letter covers recent advancements in prevention, detection and treatment.

Everyone knows the summer sun can hurt you in ways far beyond the immediate pain of a nasty burn.

The chemotherapeutic agent is currently being studied as treatment for Grade II and Grade III canine mast cell tumours where curative surgery cannot be performed.

A Four researchers at the Virginia Bioinformatics Institute at Virginia Tech and their colleagues at the Wake Forest University School of Medicine are advocating the use of systems biology as an innovative clinical approach to cancer.

Bioniche Life Sciences Inc. and Endo Pharmaceuticals jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin in the U.S. with an option for global rights.

The death toll for common cancers has dropped to its lowest level for 40 years, according to new figures.

A third of women diagnosed with breast cancer have gone through unnecessary treatments, a study has revealed A third of women diagnosed with breast cancer have gone through unnecessary treatments, a study revealed yesterday.

An antibiotic pill originally developed to help prevent rejection in organ transplant patients helps mice live longer and might offer a route to fighting age-related disease in people, U.S. researchers reported Monday.

Main Category: Prostate / Prostate Cancer Also Included In: Clinical Trials / Drug Trials Article Date: 08 Jul 2009 For the last six years, doctors have faced a dilemma about whether to treat men at risk of prostate cancer with the drug finasteride.

DOR BioPharma, Inc. , a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle technology for the improved oral delivery of drugs.

Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc. Submitted by admin on 7/6/2009 @ 5:11 AM Companies mentioned in this article: Delcath Systems, Inc.

Fewer than half of all Americans trust that their health insurance plans would pay for the full costs of cancer treatment and nearly two-thirds falsely believe Medicare would not pay anything, according to a survey released on Wednesday.

Main Category: Breast Cancer Also Included In: Cosmetic Medicine / Plastic Surgery Article Date: 08 Jul 2009 - 2:00 PDT Despite the increase of breast reconstruction procedures performed in 2008, nearly 70 percent of women who are eligible for the procedure are not informed of the reconstructive options available to them, according to a recently ...

A compound found in the soil of remote Easter Island stunningly boosts the lifespan of mice, enabling some to live more than 100 years in human terms, researchers reported Wednesday.

Main Category: Breast Cancer Also Included In: Prostate / Prostate Cancer ; Ovarian Cancer Article Date: 08 Jul 2009 - 3:00 PDT printer friendly view / write opinions rate article Black women diagnosed with breast cancer have a greater chance of dying from the disease than white women, according to a new study published online July 7 in the Journal ...

Before that awful diagnosis, Ronald Cleveland had the world by its tail. He was healthy, happy.

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

Fewer than half of all Americans trust that their health insurance plans would pay for the full costs of cancer treatment and nearly two-thirds falsely believe Medicare would not pay anything, according to a survey released on Wednesday.

The latest approval is for ALIMTA as a maintenance therapy for locally advanced or metastatic non-small cell lung cancer , specifically for patients with a nonsquamous histology whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

I'I I'IsIYI I I©I I- I I I IYI -BW-Celgene International Sarl. July 7, 2009 05:30 UTC Celgene Announces New Drug Application Filing for REVLIMID? in Japan REVLIMID filing based on safety and efficacy results of two large, randomised pivotal Phase III trials, as well as specific Japanese studies NDA is for REVLIMID in combination with ...